IMMUCELL CORPICCCEarnings & Financial Report
ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.
ICCC Q3 FY2025 Key Financial Metrics
Revenue
$5.5M
Gross Profit
$2.4M
Operating Profit
$20.1K
Net Profit
$-139.7K
Gross Margin
42.9%
Operating Margin
0.4%
Net Margin
-2.5%
YoY Growth
-8.4%
EPS
$-0.02
IMMUCELL CORP Q3 FY2025 Financial Summary
IMMUCELL CORP reported revenue of $5.5M (down 8.4% YoY) for Q3 FY2025, with a net profit of $-139.7K (up 80.1% YoY) (-2.5% margin). Cost of goods sold was $3.1M, operating expenses totaled $2.3M.
Key Financial Metrics
| Total Revenue | $5.5M |
|---|---|
| Net Profit | $-139.7K |
| Gross Margin | 42.9% |
| Operating Margin | 0.4% |
| Report Period | Q3 FY2025 |
IMMUCELL CORP Annual Revenue by Year
IMMUCELL CORP annual revenue history includes year-by-year totals (for example, 2024 revenue was $26.5M).
IMMUCELL CORP Quarterly Revenue & Net Profit History
IMMUCELL CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $5.5M | -8.4% | $-139.7K | -2.5% |
| Q2 FY2025 | $6.4M | +17.8% | $501.9K | 7.8% |
| Q1 FY2025 | $8.1M | +11.2% | $1.4M | 17.9% |
| Q4 FY2024 | $7.8M | +52.1% | N/A | N/A |
| Q3 FY2024 | $6.0M | +11.4% | $-701.7K | -11.7% |
| Q2 FY2024 | $5.5M | +54.9% | $-1.5M | -28.0% |
| Q1 FY2024 | $7.3M | +110.6% | $-437.9K | -6.0% |
| Q4 FY2023 | $5.1M | — | N/A | N/A |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | $7.3M | $5.5M | $6.0M | $7.8M | $8.1M | $6.4M | $5.5M |
| YoY Growth | N/A | 110.6% | 54.9% | 11.4% | 52.1% | 11.2% | 17.8% | -8.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $43.8M | $43.1M | $41.9M | $44.4M | $45.1M | $45.6M | $46.7M | $45.7M |
| Liabilities | $18.8M | $18.4M | $18.4M | $18.0M | $17.6M | $16.6M | $16.9M | $15.9M |
| Equity | $25.0M | $24.6M | $23.5M | $26.4M | $27.5M | $29.0M | $29.9M | $29.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-723071 | $418505 | $581780 | $-639331 | $-3051 | $1.6M | $1.6M | $-1.2M |